Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of estradiol suppression between Zoladex 10.8 mg 3‑monthly and Zoladex 3.6 mg monthly in premenopausal ER-positive early breast cancer
jRCT2080220258Phase 2
- Sponsor
- AstraZeneca
- Start
- Jun 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of goserelin in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Estradiol suppression comparison.
02
Drugs
goserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080220258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220258.